| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 18 | 2023 | 5097 | 2.240 |
Why?
|
| Malaria | 4 | 2024 | 213 | 1.820 |
Why?
|
| Spatial Analysis | 4 | 2024 | 10 | 1.780 |
Why?
|
| Anti-HIV Agents | 7 | 2022 | 1324 | 1.670 |
Why?
|
| Exercise Therapy | 3 | 2019 | 14 | 1.650 |
Why?
|
| Humans | 59 | 2025 | 14537 | 1.630 |
Why?
|
| Female | 38 | 2025 | 9103 | 1.230 |
Why?
|
| Socioeconomic Factors | 8 | 2024 | 411 | 1.200 |
Why?
|
| Machine Learning | 3 | 2023 | 22 | 1.170 |
Why?
|
| Bayes Theorem | 8 | 2022 | 81 | 1.130 |
Why?
|
| Male | 33 | 2024 | 6754 | 1.030 |
Why?
|
| Adult | 32 | 2025 | 5913 | 1.030 |
Why?
|
| Middle Aged | 27 | 2025 | 3601 | 0.980 |
Why?
|
| Endometrial Neoplasms | 1 | 2025 | 2 | 0.970 |
Why?
|
| Geographic Information Systems | 1 | 2024 | 6 | 0.960 |
Why?
|
| Risk Factors | 12 | 2025 | 1475 | 0.920 |
Why?
|
| Zimbabwe | 5 | 2023 | 120 | 0.900 |
Why?
|
| Arthritis, Rheumatoid | 10 | 2015 | 158 | 0.900 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 9 | 0.900 |
Why?
|
| South Africa | 32 | 2025 | 7596 | 0.890 |
Why?
|
| Patient Dropouts | 1 | 2023 | 18 | 0.880 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 239 | 0.880 |
Why?
|
| Maternal-Child Health Services | 1 | 2023 | 11 | 0.870 |
Why?
|
| Models, Statistical | 2 | 2021 | 55 | 0.830 |
Why?
|
| HIV | 2 | 2023 | 380 | 0.830 |
Why?
|
| Epidemics | 1 | 2022 | 65 | 0.770 |
Why?
|
| Activities of Daily Living | 2 | 2014 | 41 | 0.750 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2018 | 324 | 0.750 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 47 | 0.720 |
Why?
|
| Quality of Life | 3 | 2019 | 177 | 0.690 |
Why?
|
| Amputation | 1 | 2019 | 4 | 0.680 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 4 | 0.680 |
Why?
|
| Lower Extremity | 1 | 2019 | 10 | 0.670 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 131 | 0.670 |
Why?
|
| Home Care Services | 1 | 2019 | 15 | 0.670 |
Why?
|
| Adolescent | 14 | 2024 | 2985 | 0.670 |
Why?
|
| Exercise | 3 | 2019 | 205 | 0.640 |
Why?
|
| Contraception | 1 | 2019 | 90 | 0.610 |
Why?
|
| Young Adult | 13 | 2024 | 2498 | 0.600 |
Why?
|
| Prevalence | 8 | 2024 | 1192 | 0.570 |
Why?
|
| Rural Population | 5 | 2023 | 654 | 0.570 |
Why?
|
| Health Surveys | 2 | 2015 | 59 | 0.530 |
Why?
|
| Disability Evaluation | 3 | 2014 | 22 | 0.530 |
Why?
|
| Severity of Illness Index | 8 | 2014 | 253 | 0.530 |
Why?
|
| Child, Preschool | 7 | 2024 | 1748 | 0.520 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2016 | 6 | 0.520 |
Why?
|
| Muscle Strength | 1 | 2016 | 5 | 0.520 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 12 | 0.480 |
Why?
|
| Walking | 1 | 2014 | 14 | 0.480 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 253 | 0.470 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 48 | 0.470 |
Why?
|
| Aged | 8 | 2025 | 1740 | 0.460 |
Why?
|
| Infant | 7 | 2024 | 2244 | 0.450 |
Why?
|
| Kenya | 4 | 2023 | 183 | 0.450 |
Why?
|
| Autoantibodies | 6 | 2015 | 49 | 0.440 |
Why?
|
| Natural Language Processing | 2 | 2024 | 6 | 0.440 |
Why?
|
| Cohort Studies | 8 | 2025 | 967 | 0.430 |
Why?
|
| Cross-Sectional Studies | 10 | 2018 | 1422 | 0.430 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2013 | 2 | 0.430 |
Why?
|
| Surveys and Questionnaires | 8 | 2019 | 563 | 0.430 |
Why?
|
| Fluconazole | 1 | 2012 | 17 | 0.410 |
Why?
|
| Drug Resistance, Fungal | 1 | 2012 | 13 | 0.410 |
Why?
|
| Mental Disorders | 1 | 2013 | 44 | 0.410 |
Why?
|
| Candida albicans | 1 | 2012 | 15 | 0.400 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 34 | 0.400 |
Why?
|
| Antifungal Agents | 1 | 2012 | 40 | 0.400 |
Why?
|
| Cytokines | 4 | 2015 | 107 | 0.390 |
Why?
|
| Child | 6 | 2024 | 2242 | 0.390 |
Why?
|
| Stroke | 1 | 2012 | 62 | 0.390 |
Why?
|
| Follow-Up Studies | 3 | 2022 | 370 | 0.380 |
Why?
|
| Lost to Follow-Up | 2 | 2022 | 62 | 0.370 |
Why?
|
| Poverty | 2 | 2011 | 152 | 0.370 |
Why?
|
| Antirheumatic Agents | 4 | 2015 | 35 | 0.350 |
Why?
|
| Logistic Models | 5 | 2022 | 254 | 0.340 |
Why?
|
| Hospitalization | 1 | 2013 | 418 | 0.340 |
Why?
|
| Disabled Persons | 2 | 2012 | 23 | 0.340 |
Why?
|
| Developing Countries | 2 | 2015 | 400 | 0.330 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 5 | 0.320 |
Why?
|
| Aftercare | 2 | 2019 | 10 | 0.320 |
Why?
|
| Age Factors | 2 | 2025 | 370 | 0.320 |
Why?
|
| Abortion, Induced | 2 | 2019 | 16 | 0.320 |
Why?
|
| Retrospective Studies | 5 | 2024 | 799 | 0.310 |
Why?
|
| Autopsy | 3 | 2024 | 140 | 0.310 |
Why?
|
| Pregnancy | 4 | 2023 | 1862 | 0.300 |
Why?
|
| Malawi | 3 | 2022 | 87 | 0.300 |
Why?
|
| Acute-Phase Proteins | 3 | 2013 | 14 | 0.300 |
Why?
|
| Time Factors | 6 | 2015 | 507 | 0.290 |
Why?
|
| Regression Analysis | 3 | 2025 | 133 | 0.280 |
Why?
|
| Infant, Newborn | 3 | 2023 | 1479 | 0.270 |
Why?
|
| Cause of Death | 2 | 2024 | 221 | 0.260 |
Why?
|
| Antihypertensive Agents | 2 | 2017 | 64 | 0.260 |
Why?
|
| Health Status | 3 | 2016 | 111 | 0.260 |
Why?
|
| Cluster Analysis | 2 | 2015 | 65 | 0.240 |
Why?
|
| Case-Control Studies | 3 | 2023 | 480 | 0.240 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 468 | 0.240 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 163 | 0.240 |
Why?
|
| Nigeria | 1 | 2024 | 49 | 0.240 |
Why?
|
| Data Mining | 1 | 2024 | 8 | 0.240 |
Why?
|
| Mortality | 1 | 2025 | 104 | 0.230 |
Why?
|
| Spatial Regression | 1 | 2023 | 1 | 0.230 |
Why?
|
| Occupations | 1 | 2023 | 13 | 0.230 |
Why?
|
| Democratic Republic of the Congo | 1 | 2023 | 10 | 0.220 |
Why?
|
| Single-Blind Method | 2 | 2022 | 17 | 0.220 |
Why?
|
| Social Media | 1 | 2023 | 7 | 0.220 |
Why?
|
| Tanzania | 1 | 2023 | 88 | 0.220 |
Why?
|
| Body Mass Index | 3 | 2014 | 321 | 0.220 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2021 | 656 | 0.220 |
Why?
|
| Residence Characteristics | 1 | 2023 | 57 | 0.220 |
Why?
|
| Incidence | 2 | 2023 | 685 | 0.210 |
Why?
|
| Peptides, Cyclic | 2 | 2015 | 8 | 0.210 |
Why?
|
| Behavior Therapy | 1 | 2022 | 11 | 0.210 |
Why?
|
| Biomarkers | 5 | 2019 | 327 | 0.210 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2016 | 472 | 0.200 |
Why?
|
| Malaria, Falciparum | 1 | 2022 | 39 | 0.200 |
Why?
|
| Disease Progression | 2 | 2021 | 154 | 0.200 |
Why?
|
| Uganda | 3 | 2022 | 197 | 0.200 |
Why?
|
| Kidney | 1 | 2022 | 46 | 0.200 |
Why?
|
| Information Storage and Retrieval | 1 | 2022 | 13 | 0.200 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 13 | 0.200 |
Why?
|
| Treatment Outcome | 5 | 2016 | 889 | 0.200 |
Why?
|
| Algorithms | 1 | 2022 | 106 | 0.200 |
Why?
|
| Health Facilities | 2 | 2019 | 40 | 0.200 |
Why?
|
| Feeding Behavior | 2 | 2012 | 60 | 0.190 |
Why?
|
| Supervised Machine Learning | 1 | 2021 | 4 | 0.190 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 69 | 0.190 |
Why?
|
| Depression | 1 | 2022 | 121 | 0.190 |
Why?
|
| Probability | 1 | 2021 | 27 | 0.190 |
Why?
|
| Hypertension | 2 | 2017 | 419 | 0.190 |
Why?
|
| Markov Chains | 1 | 2021 | 22 | 0.190 |
Why?
|
| Disaster Planning | 1 | 2020 | 2 | 0.180 |
Why?
|
| Emergencies | 1 | 2020 | 16 | 0.180 |
Why?
|
| Viral Load | 2 | 2021 | 819 | 0.170 |
Why?
|
| Time and Motion Studies | 1 | 2019 | 3 | 0.170 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 6 | 0.170 |
Why?
|
| Postural Balance | 1 | 2019 | 2 | 0.170 |
Why?
|
| Schizophrenic Psychology | 1 | 2019 | 2 | 0.170 |
Why?
|
| Child Abuse, Sexual | 1 | 2019 | 4 | 0.170 |
Why?
|
| Schizophrenia | 1 | 2019 | 4 | 0.170 |
Why?
|
| Child Abuse | 1 | 2019 | 10 | 0.170 |
Why?
|
| Mentors | 1 | 2019 | 16 | 0.170 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2019 | 2 | 0.160 |
Why?
|
| Mother-Child Relations | 1 | 2019 | 20 | 0.160 |
Why?
|
| Fibroblast Growth Factors | 1 | 2019 | 5 | 0.160 |
Why?
|
| Contraceptive Effectiveness | 1 | 2019 | 2 | 0.160 |
Why?
|
| Pregnancy, Unplanned | 1 | 2019 | 19 | 0.160 |
Why?
|
| Contraception Behavior | 1 | 2019 | 54 | 0.160 |
Why?
|
| Family Planning Services | 1 | 2019 | 46 | 0.160 |
Why?
|
| Mining | 1 | 2018 | 41 | 0.150 |
Why?
|
| Counseling | 1 | 2019 | 143 | 0.150 |
Why?
|
| Occupational Diseases | 1 | 2018 | 40 | 0.150 |
Why?
|
| Mothers | 1 | 2019 | 195 | 0.150 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 96 | 0.140 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2017 | 21 | 0.140 |
Why?
|
| Health Policy | 1 | 2018 | 140 | 0.140 |
Why?
|
| Home Childbirth | 1 | 2016 | 5 | 0.140 |
Why?
|
| Latent Tuberculosis | 1 | 2016 | 45 | 0.130 |
Why?
|
| Delivery, Obstetric | 1 | 2016 | 79 | 0.130 |
Why?
|
| Urban Health | 2 | 2016 | 78 | 0.130 |
Why?
|
| Methotrexate | 2 | 2015 | 17 | 0.130 |
Why?
|
| Pain | 1 | 2016 | 41 | 0.130 |
Why?
|
| Morbidity | 1 | 2015 | 37 | 0.120 |
Why?
|
| Demography | 1 | 2015 | 105 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 22 | 0.120 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 11 | 0.120 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 9 | 0.120 |
Why?
|
| Waist-Hip Ratio | 1 | 2014 | 29 | 0.120 |
Why?
|
| Analysis of Variance | 1 | 2014 | 64 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 187 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2014 | 28 | 0.120 |
Why?
|
| Phenotype | 2 | 2012 | 158 | 0.120 |
Why?
|
| Marital Status | 1 | 2014 | 11 | 0.120 |
Why?
|
| Community Health Services | 1 | 2014 | 58 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2014 | 89 | 0.120 |
Why?
|
| Health Services Research | 1 | 2014 | 58 | 0.120 |
Why?
|
| Rural Health Services | 1 | 2014 | 48 | 0.120 |
Why?
|
| Blood Glucose | 1 | 2014 | 107 | 0.110 |
Why?
|
| Body Weight | 1 | 2014 | 111 | 0.110 |
Why?
|
| Observer Variation | 1 | 2014 | 15 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 44 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 280 | 0.110 |
Why?
|
| Leg | 1 | 2014 | 21 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 55 | 0.110 |
Why?
|
| Research Design | 1 | 2014 | 124 | 0.110 |
Why?
|
| Opportunistic Infections | 2 | 2014 | 10 | 0.110 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2013 | 5 | 0.110 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2013 | 2 | 0.110 |
Why?
|
| Psychiatric Department, Hospital | 1 | 2013 | 2 | 0.110 |
Why?
|
| Law Enforcement | 1 | 2013 | 3 | 0.110 |
Why?
|
| Police | 1 | 2013 | 4 | 0.110 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 103 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 217 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2013 | 57 | 0.100 |
Why?
|
| Mycology | 1 | 2012 | 1 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2013 | 54 | 0.100 |
Why?
|
| Rheumatoid Nodule | 1 | 2012 | 2 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2012 | 6 | 0.100 |
Why?
|
| Colony Count, Microbial | 1 | 2012 | 14 | 0.100 |
Why?
|
| Culture Media | 1 | 2012 | 15 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2014 | 240 | 0.100 |
Why?
|
| Maternal Mortality | 1 | 2013 | 58 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2012 | 27 | 0.100 |
Why?
|
| Temperature | 1 | 2012 | 56 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2012 | 52 | 0.100 |
Why?
|
| Sex Factors | 1 | 2013 | 227 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2014 | 317 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2010 | 35 | 0.100 |
Why?
|
| Adolescent Development | 1 | 2012 | 13 | 0.100 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2012 | 2 | 0.100 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Skin Physiological Phenomena | 1 | 2012 | 5 | 0.100 |
Why?
|
| Sulfasalazine | 1 | 2011 | 4 | 0.100 |
Why?
|
| Sexual Behavior | 1 | 2014 | 320 | 0.100 |
Why?
|
| Chloroquine | 1 | 2011 | 10 | 0.100 |
Why?
|
| Prednisone | 1 | 2011 | 17 | 0.100 |
Why?
|
| Phylogeny | 1 | 2012 | 231 | 0.100 |
Why?
|
| Mathematical Computing | 1 | 2011 | 2 | 0.100 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 17 | 0.100 |
Why?
|
| Space-Time Clustering | 1 | 2011 | 6 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 60 | 0.100 |
Why?
|
| Scleroderma, Systemic | 1 | 2012 | 43 | 0.100 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2011 | 14 | 0.100 |
Why?
|
| Child, Orphaned | 1 | 2011 | 16 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 106 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2012 | 175 | 0.090 |
Why?
|
| Child Mortality | 1 | 2011 | 96 | 0.090 |
Why?
|
| Rheumatoid Factor | 1 | 2010 | 16 | 0.090 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 2009 | 2 | 0.080 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 265 | 0.080 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2009 | 12 | 0.080 |
Why?
|
| Obesity | 1 | 2012 | 367 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 31 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2019 | 1160 | 0.080 |
Why?
|
| Radiography | 3 | 2013 | 80 | 0.080 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 125 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 293 | 0.070 |
Why?
|
| Narration | 1 | 2024 | 10 | 0.060 |
Why?
|
| Family Characteristics | 2 | 2016 | 135 | 0.060 |
Why?
|
| Urban Population | 2 | 2016 | 257 | 0.050 |
Why?
|
| Smoking | 2 | 2015 | 100 | 0.050 |
Why?
|
| Merozoites | 1 | 2022 | 1 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 279 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 26 | 0.050 |
Why?
|
| Computers | 1 | 2022 | 5 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 171 | 0.050 |
Why?
|
| Cystatin C | 1 | 2022 | 9 | 0.050 |
Why?
|
| Creatinine | 1 | 2022 | 53 | 0.050 |
Why?
|
| Fast Foods | 2 | 2012 | 7 | 0.050 |
Why?
|
| Energy Intake | 2 | 2012 | 24 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 179 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 188 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 62 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 244 | 0.050 |
Why?
|
| Diet | 2 | 2012 | 109 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 435 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2011 | 46 | 0.040 |
Why?
|
| Capacity Building | 1 | 2020 | 32 | 0.040 |
Why?
|
| Models, Psychological | 1 | 2019 | 2 | 0.040 |
Why?
|
| Government Programs | 1 | 2019 | 30 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 52 | 0.040 |
Why?
|
| Animals | 1 | 2022 | 1081 | 0.040 |
Why?
|
| Parathyroid Hormone | 1 | 2019 | 13 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 124 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 376 | 0.040 |
Why?
|
| Genomics | 1 | 2019 | 109 | 0.040 |
Why?
|
| Silicosis | 1 | 2018 | 8 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2018 | 203 | 0.040 |
Why?
|
| Health Personnel | 1 | 2019 | 231 | 0.040 |
Why?
|
| Ghana | 1 | 2016 | 67 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2016 | 49 | 0.030 |
Why?
|
| Maternal Health Services | 1 | 2016 | 52 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2017 | 151 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 79 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 21 | 0.030 |
Why?
|
| Rwanda | 1 | 2014 | 30 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2014 | 11 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 26 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 12 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 35 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2014 | 120 | 0.030 |
Why?
|
| Wrist Joint | 1 | 2013 | 3 | 0.030 |
Why?
|
| Ankle Joint | 1 | 2013 | 4 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 442 | 0.030 |
Why?
|
| Private Sector | 1 | 2014 | 45 | 0.030 |
Why?
|
| Matrilin Proteins | 1 | 2013 | 2 | 0.030 |
Why?
|
| Prognosis | 1 | 2013 | 199 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2016 | 329 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 150 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2012 | 12 | 0.030 |
Why?
|
| Leisure Activities | 1 | 2012 | 9 | 0.030 |
Why?
|
| Micronutrients | 1 | 2012 | 11 | 0.020 |
Why?
|
| Television | 1 | 2012 | 7 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 11 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 23 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2012 | 43 | 0.020 |
Why?
|
| Uncompensated Care | 1 | 2011 | 2 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2012 | 82 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 38 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 40 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 38 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 12 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Chemokines | 1 | 2011 | 9 | 0.020 |
Why?
|
| Body Composition | 1 | 2012 | 153 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 45 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2009 | 37 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 385 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2009 | 198 | 0.020 |
Why?
|